In future work, we plan to evaluate the in vivo efficacy of KRGE and its constituents in animal models that exhibit tau-related pathology such as the triple-transgenic mouse model of AD, which exhibits both Aβ and tau pathology, and P301S tau transgenic mice (a human tauopathy model). The gene discussed is MAPT; the disease is Alzheimer disease.